Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Oncology · Phase I

Oncology programs at Phase I — ClinicalTrials.gov pipeline intelligence.

Programs 1,319

Quick answer

Oncology Phase I programs: NovaPharmaNews indexes 1,319 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Pipeline programs

Page 17 of 28

  1. KXV01 TCR Lentinvivo Injection

    The First People's Hospital of Lianyungang

    Advanced Solid Tumors

    phase 1 small molecule active

    1 trial

  2. LB-100 for Injection

    LIXTE BIOTECHNOLOGY HOLDINGS, INC.

    Tumors

    phase 1 small molecule completed

    1 trial

  3. LB1901

    Nanjing Legend Biotech Co.

    T-Cell Lymphoma

    phase 1 mab active

    1 trial

  4. LB1908

    Nanjing Legend Biotech Co.

    Gastric Cancer

    phase 1 mab active

    1 trial

  5. LB2102

    Nanjing Legend Biotech Co.

    Small Cell Lung Cancer Extensive Stage

    phase 1 mab active

    1 trial

  6. LCAR-AIO Cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Lymphocytic Leukemia

    phase 1 mab terminated

    1 trial

  7. LCAR-AIO cells product

    Nanjing Legend Biotech Co.

    B-cell Lymphoma Recurrent

    phase 1 mab terminated

    1 trial

  8. LCAR-AMDR Cells Product

    Nanjing Legend Biotech Co.

    Acute Myeloid Leukemia

    phase 1 mab terminated

    1 trial

  9. LCAR-C182A cells

    Nanjing Legend Biotech Co.

    Gastric Cancer

    phase 1 mab terminated

    1 trial

  10. LCAR-C18S cells

    Nanjing Legend Biotech Co.

    Solid Tumors, Adult

    phase 1 mab terminated

    1 trial

  11. LCAR-G08 cells

    Nanjing Legend Biotech Co.

    Advanced Gastrointestinal Tumors

    phase 1 mab terminated

    1 trial

  12. LCAR-HL30 cells

    Nanjing Legend Biotech Co.

    Hodgkin's Lymphoma

    phase 1 mab active

    1 trial

  13. LCAR-M23 cells

    Nanjing Legend Biotech Co.

    Epithelial Ovarian Cancer

    phase 1 mab terminated

    1 trial

  14. LDK378

    Novartis Pharmaceuticals

    Anaplastic Lymphoma Kinase (ALK)

    phase 1 small molecule completed

    1 trial

  15. LEE011

    Novartis Pharmaceuticals

    Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer

    phase 1 small molecule completed

    1 trial

  16. LENVIMA hard capsules for Advanced Renal Cell Carcinoma

    AstraZeneca AB

    Advanced Renal Cell Carcinoma

    phase 1 small molecule active

    1 trial

  17. LN-144

    Iovance Biotherapeutics B.V.

    Stage IIIB Melanoma

    phase 1 mab terminated

    1 trial

  18. LN-145/LN-144

    Iovance Biotherapeutics B.V.

    Soft Tissue Sarcoma

    phase 1 mab active

    1 trial

  19. LOXO-ENC-23001

    Eli Lilly Co.

    Advanced/metastatic solid tumor

    phase 1 other active

    1 trial

  20. LOXO-FRA-24001

    Eli Lilly Co.

    Ovarian cancer, endometrial cancer, cervical cancer, non-small cell lung cancer, triple-negative breast cancer, pancreatic cancer and colorectal cancer.

    phase 1 other active

    1 trial

  21. LOXO-LNC-24001

    Eli Lilly Co.

    Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors

    phase 1 other active

    1 trial

  22. LOXO-PIK-21001

    Eli Lilly Co.

    Advanced Breast Cancer and Other Solid Tumors

    phase 1 other active

    1 trial

  23. LUCAR-20S CAR-T cells

    Nanjing Legend Biotech Co.

    Diffuse Large B Cell Lymphoma

    phase 1 small molecule terminated

    1 trial

  24. LUCAR-20SP cells

    Nanjing Legend Biotech Co.

    Relapsed B-cell Non-Hodgkin Lymphoma

    phase 1 mab active

    1 trial

  25. LUCAR-E9D or LUCAR-E9K cells product

    The First People's Hospital of Lianyungang

    B-cell Non-Hodgkin Lymphoma Recurrent B-cell Non-Hodgkin Lymphoma Refractory

    phase 1 mab active

    1 trial

  26. LUCAR-G39D cells product

    Nanjing Legend Biotech Co.

    B-Cell Non-Hodgkin Lymphoma-Recurrent

    phase 1 mab active

    1 trial

  27. LUCAR-G39P cells product

    The First People's Hospital of Lianyungang

    Relapsed and Refractory B-cell Non-Hodgkin Lymphoma

    phase 1 mab terminated

    1 trial

  28. LY3039478

    Eli Lilly and Company

    Advanced Solid Tumor

    phase 1 small molecule completed

    1 trial

  29. LY3484356

    Eli Lilly and Company

    Breast Neoplasms

    phase 1 small molecule active

    1 trial

  30. Larotinib

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Esophageal Cancer

    phase 1 small molecule active

    1 trial

  31. Lenalidomide (CC-5013)

    BRIGHT MINDS BIOSCIENCES INC.

    Advanced Solid Tumors

    phase 1 small molecule active

    1 trial

  32. Lenvatinib

    The First People's Hospital of Lianyungang

    Hepatocellular Carcinoma Stage IIIa

    phase 1 small molecule active

    1 trial

  33. Letrozole

    Context Therapeutics

    Metastatic Breast Cancer

    phase 1 small molecule terminated

    1 trial

  34. Lifileucel (LN-144)

    Iovance Biotherapeutics B.V.

    Metastatic Melanoma

    phase 1 mab active

    1 trial

  35. Lifileucel (LN-144/LN-145)

    Iovance Biotherapeutics B.V.

    Uveal Melanoma

    phase 1 mab active

    1 trial

  36. Lifirafenib

    BEONE MEDICINES AUS PTY LTD

    Solid Tumor, Adult

    phase 1 small molecule completed

    1 trial

  37. Linperlisib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Relapsed/Refractory Large Granular T Lymphocytic Leukemia

    phase 1 small molecule completed

    1 trial

  38. Lipegfilgrastim

    Teva Pharma GmbH

    Ewing Family of Tumors, Rhabdomyosarcoma

    phase 1 small molecule completed

    1 trial

  39. Liposomal Mitoxantrone Hydrochloride dose level 1

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non Hodgkin Lymphoma

    phase 1 small molecule active

    1 trial

  40. Lipotecan

    Taiwan Liposome Company

    Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial

  41. Livmoniplimab, Budigalimab

    AbbVie Deutschland GmbH & Co. KG

    Locally Advanced or Metastatic Solid Tumors, Solid Tumors

    phase 1 small molecule active

    1 trial

  42. Loncastuximab Tesirine

    ADC Therapeutics SA

    B-Cell Non-Hodgkin Lymphoma

    phase 1 small molecule active

    1 trial

  43. Loncastuximab Tesirine and Acalabrutinib

    ADC Therapeutics SA

    Chronic Lymphocytic Leukemia

    phase 1 small molecule active

    1 trial

  44. Loncastuximab Tesirine and Durvalumab

    ADC Therapeutics SA

    Diffuse Large B-Cell Lymphoma

    phase 1 small molecule terminated

    1 trial

  45. Loncastuximab tesirine and rituximab (Lonca-R)

    ADC Therapeutics SA

    Central Nervous System Lymphoma

    phase 1 small molecule active

    1 trial

  46. Low Dose MSH2-/- tumor cell vaccine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    pMMR/MSS Advanced Colorectal Cancer

    phase 1 mab active

    1 trial

  47. Lurbinectedin

    Jazz Pharmaceuticals Ireland Limited

    Extensive Stage Lung Small Cell Carcinoma

    phase 1 small molecule active

    1 trial

  48. M16-573

    AbbVie Deutschland GmbH & Co. KG

    Patients with relapsed or refractory solid tumors, including: Small cell lung cancer (SCLC); Non-small cell cancer (NSCLC); Breast cancer

    phase 1 other active

    1 trial

Frequently asked questions

How many oncology Phase I programs exist?

1,319 programs match both the therapeutic area and stage filters in our published index.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.